129 related articles for article (PubMed ID: 38884296)
41. Imatinib mesylate-induced acute hepatotoxicity.
Frikha I; Fakhfakh Y; Sahnoun R; Chtourou L; Medhaffar M; Elloumi M
J Oncol Pharm Pract; 2023 Dec; 29(8):2027-2030. PubMed ID: 37464887
[TBL] [Abstract][Full Text] [Related]
42. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
43. Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.
Eşkazan AE
Br J Clin Pharmacol; 2020 Sep; 86(9):1790-1792. PubMed ID: 32383276
[No Abstract] [Full Text] [Related]
44. Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia.
Larson JS; Bergstrom LK; Cameron JD; Erickson LA; Grimm TE
Arch Ophthalmol; 2007 Jul; 125(7):985-6. PubMed ID: 17620589
[No Abstract] [Full Text] [Related]
45. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
Ramar K; Potti A; Mehdi SA
J Clin Oncol; 2003 Jan; 21(1):172-3. PubMed ID: 12506189
[No Abstract] [Full Text] [Related]
46. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
[TBL] [Abstract][Full Text] [Related]
47. Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice.
Ielo C; Scalzulli E; Carmosino I; Pepe S; Bisegna ML; Martelli M; Breccia M
Leuk Lymphoma; 2023 Dec; 64(14):2324-2326. PubMed ID: 37689986
[TBL] [Abstract][Full Text] [Related]
48. Cystic acne due to imatinib therapy for chronic myelocytic leukemia.
Hwang A; Iskandar A; Del Rosario M; Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):972-974. PubMed ID: 29498323
[TBL] [Abstract][Full Text] [Related]
49. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
Kantarjian H; Giles F; Wunderle L; Bhalla K; O'Brien S; Wassmann B; Tanaka C; Manley P; Rae P; Mietlowski W; Bochinski K; Hochhaus A; Griffin JD; Hoelzer D; Albitar M; Dugan M; Cortes J; Alland L; Ottmann OG
N Engl J Med; 2006 Jun; 354(24):2542-51. PubMed ID: 16775235
[TBL] [Abstract][Full Text] [Related]
50. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
[TBL] [Abstract][Full Text] [Related]
51. Non-Hodgkin's lymphoma developed during imatinib mesylate treatment of chronic myeloid leukemia.
Kassar O; Kahla AB; Koubaa A; Kallel F; Amor IB; Elloumi M
J Oncol Pharm Pract; 2023 Jun; 29(4):996-998. PubMed ID: 36344191
[TBL] [Abstract][Full Text] [Related]
52. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
53. Cutaneous manifestations in chronic myeloid leukemia in chronic phase treated with imatinib.
Khokar A; Malik U; Butt G; Naumeri F
Int J Dermatol; 2019 Sep; 58(9):1098-1101. PubMed ID: 31241173
[TBL] [Abstract][Full Text] [Related]
54. Case reports of chronic myeloid leukemia and tuberculosis: Is imatinib the link between the two?
Verma SP; Tripathi AK; Kumar N; Gupta SK
Indian J Tuberc; 2021 Jul; 68(3):412-415. PubMed ID: 34099212
[TBL] [Abstract][Full Text] [Related]
55. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
Dervis E; Ayer M; Akin Belli A; Barut SG
Eur J Dermatol; 2016 Apr; 26(2):133-7. PubMed ID: 26679005
[TBL] [Abstract][Full Text] [Related]
56. Clinical efficacy and safety of high-dose imatinib for chronic myeloid leukemia patients: An updated meta-analysis.
Liu Y; Fang B; Jiang J; Wang P
J Cancer Res Ther; 2016 Oct; 12(Supplement):23-26. PubMed ID: 27721246
[TBL] [Abstract][Full Text] [Related]
57. Imatinib mesylate induced erythroderma: A rare case series.
Kumar S; Mahajan BB; Kaur S; Banipal RP; Singh A
J Cancer Res Ther; 2015; 11(4):993-6. PubMed ID: 26881566
[TBL] [Abstract][Full Text] [Related]
58. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
[No Abstract] [Full Text] [Related]
59. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
[TBL] [Abstract][Full Text] [Related]
60. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
